Lipocine announces open label extension to ongoing lpcn 1144 lift study

Salt lake city, dec. 30, 2020 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is enrolling patients into an open label extension to the ongoing lpcn 1144 phase 2 lift study based...
LPCN Ratings Summary
LPCN Quant Ranking